The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives

@article{Wang2013TheER,
  title={The Emerging Role of Dipeptidyl Peptidase-4 Inhibitors in Cardiovascular Protection: Current Position and Perspectives},
  author={Xi-mei Wang and Yue-jin Yang and Yong-jian Wu},
  journal={Cardiovascular Drugs and Therapy},
  year={2013},
  volume={27},
  pages={297-307}
}
Dipeptidyl peptidase-4 (DPP-4 or CD26) inhibitors, a new class of oral anti-hyperglycemic agents that prolong the bioavailability of the endogenously secreted incretin hormone glucagon-like peptide-1 (GLP-1) and the glucose-dependent insulinotropic polypeptide (GIP), are effective in the treatment of diabetes. Accumulating data have indicated that DPP-4 inhibitors play important protective roles in the cardiovascular system. DPP-4 inhibitors act to decrease myocardial infarct size, stabilize… CONTINUE READING

5 Figures & Tables

Connections & Topics

Mentioned Connections BETA
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
DPP-4 inhibitors act to decrease myocardial infarct size , stabilize the cardiac electrophysiological state during myocardial ischemia , reduce ischemia / reperfusion injury , and prevent left ventricular remodeling after myocardial infarction .
Dipeptidyl peptidase-4 ( DPP-4 or CD26 ) inhibitors , a new class of oral anti - hyperglycemic agents that prolong the bioavailability of the endogenously secreted incretin hormone glucagon - like peptide-1 ( GLP-1 ) and the glucose - dependent insulinotropic polypeptide ( GIP ) , are effective in the treatment of diabetes .
All Topics